Background: RAS mutations have been shown to confer resistance to anti-epidermal growth factor receptor (EGFR) treatment. We analysed the results of the PETACC8 trial (cetuximab þ FOLFOX vs FOLFOX) in full RAS and BRAF wildtype (WT) patients (pts) with resected stage III colon cancer.
Introduction
The Pan-European Trials in Alimentary traCt Cancer 8 (PETACC-8) study tested FOLFOX4, with or without cetuximab, after curative resection of stage III colon cancer [1] . Promising phase II and III studies of cetuximab adjunction to FOLFOX4 in metastatic colorectal cancer showed impressive response and disease-control rates, suggesting possible synergy of this new combination [2, 3] . The PETACC-8 protocol was amended on 17 June 2008, restricting enrolment to patients with KRAS exon 2 wildtype (WT) tumours and increasing the sample size. The first analysis of the trial results was negative, with no improvement in disease-free survival (DFS) or overall survival (OS) when cetuximab was added to FOLFOX [1] .
KRAS exon 2 mutations are predictive of resistance to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer [3] [4] [5] [6] , as are activating mutations in KRAS exon 3 or 4 and in NRAS exon 2, 3 or 4 [7, 8] .
BRAF mutations are typically exclusive of RAS mutations, and clinical data suggest that the BRAF V600E mutation is predictive of poorer survival but not of anti-EGFR efficacy in patients with metastatic colorectal cancer [9, 10] , however, the low prevalence of these mutations makes it difficult to evaluate their possible biomarker status.
Patient selection based on tumour mutational status might thus improve the harm-benefit profile of anti-EGFR therapy. This has been largely demonstrated in metastatic colorectal cancer [7, 8] but not yet in the adjuvant setting. We and others recently found that BRAF V600E and KRAS exon 2 mutations were prognostic in stage III colon cancer, being associated with shorter time to recurrence (TTR), OS and survival after relapse [11] [12] [13] [14] . However, anti-EGFR efficacy has not yet been evaluated in selected patients with RAS WT and BRAF WT resected stage III colon cancer.
We used the Ampliseq colon-lung cancer panel version 2 to sequence exons 2, 3 and 4 of KRAS and NRAS, as well as BRAF exons 11 and 15, amongst those PETACC8 trial participants who consented to translational research. TTR, DFS and OS were analysed in full RAS WT patients and full RAS and BRAF WT patients. The prognostic impact of individual rare RAS and BRAF mutations was also investigated.
Materials and methods

Patients
PETACC8 trial participants underwent complete resection of histologically proven stage III colon adenocarcinoma, and were then randomly assigned to receive 6 months of either FOLFOX or FOLFOX þ cetuximab, with regular monitoring, as described elsewhere [1] . The trial started in December 2005. The protocol was amended in June 2008 to enrol only patients with KRAS exon 2 WT tumours, and the sample size was increased to maintain power of statistical analyses. The study ended on 9 November 2009. Specific written informed consent was required from each patient included in the planned translational program of the trial.
DNA extraction and mutation analysis
Tumour samples were prospectively banked. Tumour DNAs were extracted from FFPE tissues containing more than 50% of tumour cells by using the QIAamp V R DNA Mini Kit (Qiagen V R ). Molecular analysis, centralized at Georges Pompidou European Hospital, was carried out retrospectively for the 2096 patients included before the trial amendment and prospectively for the other 463 patients. KRAS hotspot mutations (c.34G > A/p.G12S, c.34G > C/p.G12R, c.34G > T/p.G12C, c.35G > A/ p.G12D, c.35G > C/p.G12A, c.35G > T/p.G12V and c.38G > A p.G13D) and the BRAF V600E mutation (c.1799T > A/p.V600E) were detected by real-time PCR with TaqMan V R probes (Applied Biosystems). The assays are alteration-specific and robustly detect 10% of mutated alleles for all the mutations tested.
Exons 2, 3 and 4 of KRAS and NRAS, as well as BRAF exons 11 and 15, were sequenced with the Ampliseq colon-lung cancer panel version 2 in the PETACC8 trial participants who consented to translational research.
Statistical analyses
TTR, DFS and OS were analysed in patients with any RAS or BRAF mutations, RAS and BRAF WT status, and rare RAS mutations. The individual prognostic value of each mutation was also analysed.
TTR was defined as the time between randomization and local or metastatic recurrence or death related to disease recurrence, whichever occurred first. DFS was defined as the time between randomization and local or metastatic recurrence or diagnosis of a second colorectal cancer, or death from any cause, whichever occurred first. OS was defined as the time between randomization and death from any cause.
For baseline comparisons, categorical factors were compared with v 2 tests and continuous factors with standard parametric or non-parametric tests, depending on their normality. Continuous variables are reported as mean (SD) and median (interquartile range, IQR) values. TTR, DFS and OS curves were estimated using the Kaplan-Meier method. Differences between groups of patients were analysed with logrank tests. Cox models, Kaplan-Meier curves and forest plots were used for all analyses. Factors included in multivariate analyses were the treatment group and baseline prognostic factors that were clinically relevant or significant in univariate analysis, namely tumour grade, pT stage, pN stage, venous embolism, lymphatic invasion (VELI), bowel obstruction/ perforation and tumour location. A two-sided significance level of 5% was applied for all analyses. Results were not adjusted for multiple comparisons. All statistical analyses were done by FFCD statisticians using SAS statistical software (version 9.4). The database was locked in July 2015.
Results
Study population
Among the 2559 patients included in the PETACC8 phase III study, 741 were KRAS exon 2 mutated and 167 were BRAF V600E mutated. Of the remaining 1651 patients, 1054 gave their written consent for translational research and had sufficient tumour material for NGS analyses. NGS failed in 62 cases. The remaining 992 patients were fully analysed. A total of 1900 patients (including RAS mutated patients) met all the criteria for full molecular analysis (informed consent, sufficient material and technical success) (supplementary Figure S1 , available at Annals of Oncology online). The patients' baseline and tumour characteristics are summarized in Table 1 . The demographic and clinical characteristics of the patients included in the molecular study (N ¼ 1900) were not significantly different from those of the entire randomized population (N ¼ 2559) (supplementary Table S1 , available at Annals of Oncology online).
RAS and BRAF mutational status
Amongst the 1900 patients included in the molecular study, 719 (38%) were double WT, 968 (51%) were RAS mutated and 213 (11%) were BRAF mutated ( Figure 1 ). KRAS, NRAS and BRAF mutation frequencies are summarized in Figure 1 .
The most frequently mutated KRAS exon was exon 2 (80.9%), followed by exons 4 (8.3%) and 3 (4.6%); two tumours (0.2%) were mutated on two different exons ( Table 2) . As expected, codon 12 was the most frequently mutated codon (75.9%), followed by codon 13 (18.4%). NRAS exons 2, 3 (codon 61) and 4 were mutated in respectively 30, 31 and 2 cases. BRAF was mutated in 213 tumours, including 192 tumours (90%) harbouring the V600E mutation. The second most frequent mutation affected codon 469, in 8 cases (3.8%). The mutations were grouped for analysis into V600E and non-V600E.
KRAS and BRAF mutations were both present in eight tumours (four V600E and four non-V600E). KRAS and NRAS mutations were both present in two tumours (KRAS pA146T associated with NRAS p.G12D and with NRAS p.A146V in one case each). NRAS and BRAF mutations were both present in three tumours, all with non-V600E BRAF mutations.
Clinical outcomes according to RAS and BRAF mutational status
As previously reported, adding cetuximab to FOLFOX did not improve TTR in the whole trial population [1] (Figure 2A ). In the RAS WT and BRAF WT population, a trend towards better outcomes was seen in the cetuximab group but the difference did In patients with RAS-mutated tumours, the addition of cetuximab to FOLFOX was associated with a trend towards poorer TTR [HR:1.14 (0.91-1.44); P ¼ 0.25] (Figure 2C Rare RAS and BRAF mutations (i.e. KRAS exon 3, 4; NRAS exons 2, 3, 4 and BRAF non-V600E) tended to be associated with a deleterious effect of cetuximab, with HRs of 1.6 for TTR (P ¼ 0.09) and 1.61 for OS (P ¼ 0.13).
Prognostic value of RAS and BRAF mutations
In the overall study population, KRAS exon 2 and BRAF V600E mutations were associated with worse outcomes when compared with RAS and BRAF WT status, as previously described [12] . This was also the case of KRAS and NRAS (exon 3) codon 61 rare mutants with respect to TTR and OS, contrary to other rare RAS or BRAF mutants (Figure 3) . The number of rare mutations was too small for meaningful multivariable analysis.
Discussion
KRAS and NRAS are closely related to RAS oncogene family members, and mutations at codon 12, 13, 61, 117 or 146 of either gene result in increased levels of guanosine triphosphate-bound RAS proteins [15, 16] . KRAS and NRAS mutations at these codons tend to be mutually exclusive in colorectal tumours, suggesting functional redundancy [17] . Mutations in HRAS, the third member of the RAS family, are infrequent in colorectal cancer [17, 18] . Clinical data suggest that RAS genes mutations are also associated with worse outcomes in the adjuvant setting [11] [12] [13] [14] .
Previous trials of anti-EGFR therapies combined with irinotecan or oxaliplatin-containing regimens showed no benefit in patients with KRAS exon 2 mutations [2, 6] . Randomized phase 3 trials of panitumumab, given alone [19] or in combination with FOLFOX or FOLFIRI [3, 5, 7] , showed no response to this anti- Figure 1 . Distribution of mutations. EGFR therapy in patients with metastatic colorectal tumours harbouring a mutation in KRAS or NRAS. This was also the case in recent analyses of randomized trials with cetuximab [8, 20] . All these studies involved patients with metastatic colorectal cancer. In contrast, we assessed here the effect of adjuvant cetuximab plus FOLFOX in patients with fully resected primary stage III colon tumours and full KRAS, NRAS and BRAF characterization.
Removing patients with rare RAS and BRAF mutations, with a poor outcome, from the target efficacy population reveals a trend to a positive effect of the addition of cetuximab to standard FOLFOX in patients with RAS and BRAF WT tumours. Although the impact Figure 2. Kaplan-Meier curves for time to relapse according to study treatment (A) in the KRAS exon 2 WT intention-to-treat population, (B) in patients with RAS WT and BRAF WT tumours, and (C) in patients with RAS-mutated tumours. TTR, time to recurrence; HR, hazard ratio.
of cetuximab was not statistically significant, it might be clinically relevant. In the MOSAIC pivotal trial, adding oxaliplatin to 5-FU improved DFS, with an HR of 0.8. Here, multivariate analysis adjusted for pT, pN, histological grade, VELI and tumour location yielded an HR of 0.76 (95% CI: 0.54-1.06). This suggests that a new randomized trial powered to demonstrate such a difference in WT colon cancer patients may be relevant, especially after a 12-year period with no advances in adjuvant treatment of stage III colon cancer. If such trial is not forthcoming, our results would have to be confirmed using at least internally (other sequencing approaches for example) and externally (on other datasets) before discussing any practice change. New markers of colon cancer sensitivity to antiEGFRs are emerging and could in future also be assessed in samples from PETACC8 and other adjuvant trials of anti-EGFRs, such as the NCCTG N0147 study, in order to generate hypotheses for future trials [21, 22] . Although adding cetuximab to FOLFOX tended to be beneficial in terms of TTR and DFS, this was not the case for OS (HR of 0.9 in adjusted analyses). This discordance between OS and TTR/ DFS suggests that survival after relapse may differ between patients who do and do not receive adjuvant cetuximab, possibly because of lower cetuximab prescription rates in the metastatic setting when patients have received adjuvant cetuximab. Further analyses of survival after recurrence, and of treatments received at recurrence, are needed to clarify this point.
A deleterious effect of cetuximab and panitumumab has been reported in some patients with RAS-mutated tumours treated with FOLFOX in the metastatic setting [7, 20] . This was not the case of patients with RAS-mutated metastatic colorectal cancer receiving irinotecan-based backbone chemotherapy [8] . In our study of stage III colon cancer, there was only a non-significant trend towards worse outcomes with cetuximab in RAS-mutant patients.
This trend towards a deleterious effect of cetuximab was even stronger in patients with rare RAS mutations, but again it did not reach statistical significance, possibly owing to the small number of patients with rare RAS mutations (n ¼ 185).
We and others have shown that KRAS exon 2 and BRAF V600E mutations are associated with a poor prognosis in stage III colon cancer and especially in the 90% of patients with MSS tumours [14] . However, the prognostic value of rare KRAS, NRAS and BRAF mutations has rarely been studied in this setting. Gavin et al. reported in 2299 stage II and III colon tumours a similar frequency of NRAS mutations (2.9%) that were associated with a worse TTR (HR ¼ 1.53; 95% CI: 1.01-2.31; P ¼ 0.04), but this difference disappeared in multivariate analysis and was not significant for OS [23] . A recent retrospective study of rare KRAS mutations at codons 12, 13 and 61 in stage II and III colon cancer patients showed no significant impact on DFS or OS [24] . However, the impact of individual KRAS mutations was not studied, the sample was quite small, and the study was retrospective. Modest et al. very recently studied the prognostic impact of RAS mutations in metastatic patients and found that only G13D and G12C had prognostic value and not rare mutations [25] . We found no recent data on the prognostic value of rare BRAF mutations in the adjuvant setting. In the metastatic setting, BRAF non-V600E-mutated tumours seem to carry a better prognosis [26] . In the present work, we found that only KRAS and NRAS codon 61 mutations had significant negative prognostic value, while other rare RAS or BRAF non-V600E mutations did not seem to affect patient outcome. However, these results need to be confirmed in larger series with full RAS and BRAF mutational analyses.
In conclusion, adding cetuximab to standard FOLFOX adjuvant therapy in stage III colon cancer results in a non-significant trend towards better outcomes in RAS and BRAF WT patients. No significant detrimental effect was observed in RAS mutant patients. Though not significant, the clinically relevant 0.76 adjusted HR observed for DFS in favour of adding cetuximab to FOLFOX in full RAS and BRAF WT stage III colon cancer pts, may justify a new randomized controlled trial testing EGFR inhibitors in this setting. 
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